ASCO is coming up, so there will be major-league oncology news next week. But some of it couldn’t wait, so…
Wyeth’s new drug (Torisel) for kidney cancer gets the OK from the FDA.
Problem drugs: a summary of the sketchy stuff behind the scenes in the ramp-up to Ketek approval (Aventis), and more commentary on the Avandia issue – focusing on the potentially high negative impact of knee-jerk cessation of treatment.
While on the subject of diabetes – a helpful article summarizing the various classes of treatment, and the spillover effect of the Avandia problems for Takeda’s Actos (which is getting a bunch of new prescriptions).
Finally, Xyzal, son of Zyrtec, approved for allergy treatment.
Might be news to you – 30 minutes